Literature DB >> 8973068

Case study: withdrawal syndrome in adolescent chronic cannabis users.

A Duffy1, R Milin.   

Abstract

Cannabis use is common among adolescents and has recently been increasing, especially among young teenagers. Whether the reduction of cannabis in chronic heavy users results in a clinically significant withdrawal syndrome is controversial. This article presents three case vignettes supporting the view that chronic cannabis use by adolescents may result in a clinically significant withdrawal syndrome and that the associated physiological symptoms directly contribute to the persistent use of the substance.

Entities:  

Mesh:

Year:  1996        PMID: 8973068     DOI: 10.1097/00004583-199612000-00013

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  5 in total

1.  Incremental validity of anxiety sensitivity in relation to marijuana withdrawal symptoms.

Authors:  Marcel O Bonn-Miller; Michael J Zvolensky; Erin C Marshall; Amit Bernstein
Journal:  Addict Behav       Date:  2006-12-19       Impact factor: 3.913

2.  Cannabis withdrawal in adolescent treatment seekers.

Authors:  Ryan Vandrey; Alan J Budney; Jody L Kamon; Catherine Stanger
Journal:  Drug Alcohol Depend       Date:  2004-12-18       Impact factor: 4.492

3.  Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice.

Authors:  O Valverde; R Maldonado; E Valjent; A M Zimmer; A Zimmer
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

Review 4.  Adolescent substance abuse treatment: evidence-based practice in outpatient services.

Authors:  Yifrah Kaminer
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

5.  Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users.

Authors:  Joanna Jacobus; Lindsay M Squeglia; Silvia Escobar; Benjamin M McKenna; Margie Mejia Hernandez; Kara S Bagot; Charles T Taylor; Marilyn A Huestis
Journal:  Psychopharmacology (Berl)       Date:  2017-09-12       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.